- Home
- BNTX vs MKL Comparison
BNTX vs MKL Comparison
Compare BNTX & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNTX | MKL |
|---|---|---|
| Founded | 2008 | 1930 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5B | 26.2B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BNTX | MKL |
|---|---|---|
| Price | $90.09 | $1,950.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 1 |
| Target Price | $134.15 | ★ $2,100.00 |
| AVG Volume (30 Days) | ★ 1.1M | 42.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 169.22 |
| Revenue | N/A | ★ $15,513,233,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.61 | $3.65 |
| P/E Ratio | ★ N/A | $11.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.81 | $1,621.89 |
| 52 Week High | $124.00 | $2,207.59 |
Technical Indicators
Market Signals| Indicator | BNTX | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 29.40 |
| Support Level | N/A | $1,889.68 |
| Resistance Level | $112.30 | $1,999.37 |
| Average True Range (ATR) | 3.26 | 34.50 |
| MACD | -2.03 | -11.19 |
| Stochastic Oscillator | 31.77 | 14.18 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.